Alterity Therapeutics
ATHE
14 hedge funds and large institutions have $230K invested in Alterity Therapeutics in 2016 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 10 closing their positions.
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
40% less capital invested
Capital invested by funds: $383K → $230K (-$153K)
42% less funds holding
Funds holding: 24 → 14 (-10)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 10
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $18K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$90.2K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$7.31K |
| 3 |
Group One Trading
Chicago,
Illinois
|
+$1.87K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
-$78K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$27K |
| 3 |
ARTA
A.R.T. Advisors
New York
|
-$24K |
| 4 |
SBIA
Sheaff Brock Investment Advisors
Indianapolis,
Indiana
|
-$8K |
| 5 |
LPL Financial
San Diego,
California
|
-$7K |
ATHE Hedge Fund Activity: Q1 2016 in Review
14 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Alterity Therapeutics (ATHE) for Q1 2016, worth a combined $230K — down 40% from $383K a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of ATHE and 0 opened new positions — a net loss of 10 holders — while 4 trimmed existing stakes and 3 added.
The largest buyer was Morgan Stanley, adding an estimated $90.2K. The largest seller was Virtu KCG Holdings, exiting entirely with an estimated $78K sold.
- 14 institutional investors held Alterity Therapeutics (ATHE) as of Q1 2016, down from 24 in Q4 2015.
- Funds reported $230K of Alterity Therapeutics stock for Q1 2016, down 40% quarter-over-quarter.
- 0 funds opened new Alterity Therapeutics positions in Q1 2016 and 10 closed out, a net change of -10 holders.
- The largest Alterity Therapeutics buyer in Q1 2016 was Morgan Stanley, an estimated $90.2K added.
- The largest Alterity Therapeutics seller in Q1 2016 was Virtu KCG Holdings, an estimated $78K sold.
Based on aggregated 13F filings for Q1 2016.